Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + cisplatin + capecitabine versus gemcitabine + cisplatin for metastatic nasopharyngeal carcinoma
ChiCTR1900027112Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel, cisplatin, capecitabine and gemcitabine in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: 7-month progression-free survival rate and progression-free survival. Started Nov 2019; status: recruiting.
02
Drugs
paclitaxelcisplatincapecitabinegemcitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1900027112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027112.